PALOMA-3 was a double-blind, placebo-controlled, multicenter phase III trial involving 521 women aged 18 years and older with HR-positive/HER2-negative ABC who progressed or relapsed within a year after receiving endocrine therapy. This evidence concerns the gene ERBB2 and aneurysmal bone cyst.